Contract

Associate Director

Finance

Updated on 8/23/2026

Zymeworks

Zymeworks

201-500 employees

Biopharmaceutical firm developing multifunctional therapeutics

Compensation Overview

CA$123.8k - CA$189.8k/yr

Vancouver, BC, Canada

Hybrid

Three days on-site per week required; the role is fixed-term for 18 months and offers no relocation or immigration support.

Category
Accounting (1)
Required Skills
NetSuite
ERP
Coupa
Excel/Numbers/Sheets

Get referred to Zymeworks

See people who can refer or advise you

Requirements
  • CPA designation in good standing.
  • 8–10+ years of progressive accounting and finance experience under United States generally accepted accounting principles.
  • Experience leading accounting teams and month-end close processes.
  • Experience with NetSuite and Coupa.
  • Ability to lead through change and uncertainty while providing clear direction, transparency, and context to team members and maintaining focus on priorities, deliverables, and business objectives.
  • Strong interpersonal and communication skills, with the ability to work collaboratively and establish and maintain effective working relationships with employees, management, and external associates.
  • Strong analytical and problem-solving skills, including the ability to work through complex accounting topics.
  • High level of accuracy and attention to detail.
  • Ability to take ownership of work and operate with minimal supervision.
  • Ability to review others’ work and provide constructive feedback.
  • Strong communication skills and ability to work cross-functionally.
  • Adaptability and willingness to work in a fast-paced, evolving environment.
  • Proficiency in Excel and familiarity with enterprise resource planning systems.
Responsibilities
  • Lead and oversee the monthly, quarterly, and year-end financial close process.
  • Review and approve complex journal entries and reconciliations, including royalty monetization, general and administrative expenses, research and development and clinical accruals, payroll, and other general ledger activities.
  • Review balance sheet reconciliations and financial reporting deliverables.
  • Support quarterly and annual reporting, technical accounting memos, and audit deliverables.
  • Lead, develop, and mentor members of the Accounting and Accounts Payable teams.
  • Establish priorities, allocate resources, and manage workloads across the team.
  • Provide coaching, feedback, and performance management support.
  • Act as the primary escalation point for accounting and accounts payable matters.
  • Oversee Accounts Payable processes and controls.
  • Drive process improvements, automation initiatives, and operational efficiencies, focusing on timely invoice payment and stakeholder communication.
  • Partner with stakeholders to improve procure-to-pay workflows.
  • Coordinate audit requests and support external audit activities.
  • Ensure compliance with accounting policies, controls, and regulatory requirements.
  • Support Sarbanes-Oxley readiness and control documentation activities.
  • Partner with FP&A, Human Resources, Payroll, Procurement, Clinical and Research and Development Operations, Information Technology, and Legal.
  • Provide accounting guidance and recommendations to stakeholders.
  • Support strategic finance and organizational initiatives, including mergers and integrations, divestitures, and financings.
  • Lead initiatives focused on scalability, automation, and operational excellence.
  • Support enterprise resource planning enhancements, testing, and implementations.
  • Develop and maintain finance procedures and documentation.
Desired Qualifications
  • Biotechnology, life sciences, or public company experience.
  • Experience with transactions such as mergers and divestitures.

Zymeworks develops multifunctional therapeutics for hard-to-treat cancers and other serious diseases. Its main products are antibody-drug conjugates (ADCs) and multispecific (bispecific) antibodies that link cancer targets to therapeutic payloads using proprietary platforms for precise engagement and modular design. The company drives discovery, preclinical work, and clinical development with an integrated R&D engine and earns revenue through partnerships, licensing, and commercialization of its own therapies. Its goal is to discover, develop, and commercialize novel therapeutic agents globally to improve outcomes for patients with difficult-to-treat cancers and other serious diseases.

Company Size

201-500

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2003

Get referred to Zymeworks

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 Ziihera GEA PDUFA can trigger Zymeworks' $250 million Jazz milestone.
  • June 2026 ZW191 Phase 1 showed 58.8% ovarian ORR and durable responses.
  • Theravance's YUPELRI cash flows should close in 2H 2026, broadening financing.

What critics are saying

  • A failed August 25, 2026 GEA review destroys the $250 million Jazz payment.
  • Q2 2026 revenue was $4.6 million; royalties still do not fund ZW191.
  • Without Ziihera and Theravance cash, Zymeworks becomes an underfunded R&D shell.

What makes Zymeworks unique

  • Ziihera, the only marketed HER2 bispecific antibody, anchors Zymeworks' royalty engine.
  • Azymetric and ZW191 payload chemistry differentiate ADCs like ZW191 and future multispecifics.
  • Zymeworks pairs internal discovery with partner commercialization, preserving upside across territories.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Company Match

Company Equity

Paid Vacation

Hybrid Work Options

Remote Work Options

Employee Share Purchase Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
GlobeNewswire
Aug 11th, 2026
Zymeworks announces participation in upcoming investor conferences.

Zymeworks announces participation in upcoming investor conferences. August 11, 2026 06:00 ET | Source: Zymeworks Inc. VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: * Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA. * Citi's Biopharma Back to School Summit: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York, NY. * Morgan Stanley Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 14 at 4:50 pm ET in New York, NY. * H.C. Wainwright Annual Global Investment Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 15 in New York, NY. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks' asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera(R)(zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric(TM) technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Investor Inquiries: Shrinal Inamdar Vice President, Investor Relations (604) 678-1388 [email protected] Media Inquiries: Diana Papove Vice President, Corporate Communications (604) 678-1388 [email protected] Company Profile Zymeworks Inc. Industry: Pharmaceuticals & Biotechnology Website: https://www.zymeworks.com/ Recommended reading.

Zymeworks Inc.
Aug 11th, 2026
Zymeworks announces participation in upcoming investor conferences.

Zymeworks announces participation in upcoming investor conferences. August 11, 2026 VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: * Wells Fargo Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 8 at 3:45 pm Eastern Time (ET) in Boston, MA. * Citi's Biopharma Back to School Summit: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 9 at 3:40 pm ET in New York, NY. * Morgan Stanley Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and fireside chat on September 14 at 4:50 pm ET in New York, NY. * H.C. Wainwright Annual Global Investment Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on September 15 at 3:30 pm ET in New York, NY. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks' asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera(R)(zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric(TM) technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Investor Inquiries: Shrinal Inamdar Vice President, Investor Relations (604) 678-1388 [email protected] Media Inquiries: Diana Papove Vice President, Corporate Communications (604) 678-1388 [email protected]

PR Newswire
Aug 10th, 2026
Zymeworks to acquire Theravance Biopharma for $17 per share in cash plus CVR

Theravance Biopharma reported second quarter 2026 financial results, showing progress on its pending acquisition by Zymeworks expected to close in the second half of 2026 for $17.00 per share in cash. YUPELRI collaboration revenue increased 11% year-over-year to $20.7 million, driven by continued net sales growth. The company's organizational restructuring delivered a 35% reduction in operating expenses year-over-year, excluding restructuring and transaction costs. TRELEGY net sales reached approximately $1.0 billion in Q2 2026, reported by GSK. The company expressed high confidence in achieving a $100 million 2026 milestone payment. Theravance Biopharma ended the quarter with a cash balance of $388 million and no debt. The company reported a net loss of $5.9 million for the quarter, compared to net income of $54.8 million in Q2 2025.

GlobeNewswire
Jul 16th, 2026
Zymeworks to report second quarter 2026 financial results on August 6, 2026.

Zymeworks to report second quarter 2026 financial results on August 6, 2026. VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026. In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, sharing greater visibility into the combined business and its strategic priorities. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks' asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera(R)(zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric(TM) technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Investor Inquiries: Shrinal Inamdar Vice President, Investor Relations (604) 678-1388 [email protected] Media Inquiries: Diana Papove Vice President, Corporate Communications (604) 678-1388 [email protected] Company Profile Zymeworks Inc. Industry: Pharmaceuticals & Biotechnology Website: https://www.zymeworks.com/ Recommended reading.

Zymeworks Inc.
Jun 29th, 2026
Zymeworks to Acquire Theravance Biopharma, Inc. | Zymeworks Inc.

Acquisition adds YUPELRI ®   (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolio Acquisition of Theravance Biopharma at $17 per share is supported by an innovative non-recourse financing